Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254803 | 1.00 | NOTUM (0.63) | NOTUMMAPTKDM4EHPGDALDH1A1 | |
| SCHEMBL25426507 | 0.85 | DGAT2 (0.53) | NOTUMMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30245937 | 0.85 | DGAT2 (0.53) | NOTUMMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16540016 | 0.83 | MAOB (0.52) | NOTUMNPC1RAB9A | |
| SCHEMBL5934873 | 0.82 | NOTUM (0.57) | NOTUMMAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL598119 | 0.81 | NOTUM (0.58) | NOTUMMAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL19540313 | 0.81 | NOTUM (0.52) | NOTUMMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL837064 | 0.81 | NOTUM (0.44) | NOTUMMAPTKDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6006151 | 0.81 | NOTUM (0.55) | NOTUMMAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL17188515 | 0.79 | LMNA (0.46) | NOTUMMAPTKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | NOTUM 3115/4885MAPT 694/4885KDM4E 813/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NOTUM 1328/4885MAPT 256/4885KDM4E 1401/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NOTUM 1272/4885MAPT 268/4885KDM4E 1325/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | NOTUM 4764/4885MAPT 561/4885KDM4E 3102/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NOTUM 1527/4885MAPT 519/4885KDM4E 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.